Skip to main content

Alzheimer’s Disease: Medical Treatments

Volume 467: debated on Thursday 22 November 2007

To ask the Secretary of State for Health what assessment his Department has made of the efficacy of (a) CAD16 and (b) PBT 2 in the treatment of Alzheimer’s disease. (166330)

The Department does not commission the clinical trails needed to generate estimates of the efficacy of specific compounds in specific diseases. Such trials are funded in competition by the Medical Research Council and the Health Technology Assessment Programme. No such work has been commissioned for CAD16 or PBT2 in Alzheimer’s disease. In terms of the assessment of existing evidence of efficacy, this was completed by the National Institute for Health and Clinical Excellence and no such review has been completed.